MCL Literature Feed

This UK real-world study confirms bendamustine-rituximab toxicity rates are similar to clinical trials, identifying MCL histology and poor performance status as key risk factors for serious infections.

This retrospective study found 36% of ibrutinib-treated patients, including MCL, developed serious infections, with prior transplant and steroid use identifying a high-risk group needing potential prophylaxis.

In a mixed lymphoma cohort, this retrospective study found cardiac involvement in 1.5% of patients, primarily DLBCL with pericardial effusion, but provides no specific data on MCL.

This real-world study shows significant MCL-related mortality after first relapse (23%), suggesting high-risk patients may not survive to receive novel therapies, supporting their use in earlier lines.

This Japanese post-marketing surveillance study confirms the real-world efficacy (59.9% ORR) and safety of ibrutinib in heavily pre-treated, elderly patients with relapsed/refractory MCL, supporting its routine use.

This study developed and validated a new lymphoma-specific patient-reported outcome measure using the EORTC Item Library, providing a crucial tool for assessing MCL symptoms in clinical trials.

This 15-year real-world study benchmarks MCL survival outcomes, reflecting evolving treatment eras and providing crucial prognostic data from routine clinical practice.

Italian real-world data highlights the poor prognosis and significant unmet clinical needs for relapsed/refractory MCL patients following covalent BTKi failure, emphasizing the urgency for novel treatment strategies.

This retrospective study outlines real-world treatment patterns for MCL from a single private practice in Brazil, providing crucial data on management outside of traditional clinical trial or academic settings.

This systematic review of real-world data supports positioning covalent BTKis as second-line therapy for relapsed/refractory MCL, followed by CAR-T cells for patients relapsing after BTKi treatment.

This retrospective review of 14 Moroccan patients describes real-world MCL clinical features and treatment patterns, providing rare epidemiological data from North Africa.

This meta-analysis of 984 R/R MCL patients confirms high CAR-T efficacy (74% CR, 69% 1-year OS), providing robust, pooled outcome data for this heavily pretreated population.

In a real-world cohort including MCL, the Hematotox-Score predicted early cytopenias post-CAR-T but not survival, underscoring the need for improved prognostic tools for toxicity management.